"
ROS1 in Squamous Non-Small Cell Lung Cancer—Combined Immunotherapy (PD1/CTLA4) or Targeted Therapy?"
written by Alexander Yakobson, Tal Mor, Levitas Dina, Laila C. Roisman, Daniel Levin, Wafeek Alguayn, Sara Morgenstern, Keren Rouvinov, Nir Peled, Waleed Kian,
published by
Journal of Cancer Therapy,
Vol.11 No.6, 2020
has been cited by the following article(s):
|
[1]
|
A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)
Cancer Cell,
2024
DOI:10.1016/j.ccell.2023.12.004
|
|
|
|